RGEN

Repligen Corp. 10-Q Summary: Quarter Ended September 30, 2001

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2001, and the six-month period ended on that date. Repligen Corporation is a biotechnology company developing therapeutic products for pediatric diseases (autism, leukemia, mitochondrial disease) and manufacturing products for therapeutic antibody production (Protein A). The company operates as a single segment.

Key Financial Metrics

Note: The filing does not explicitly state a total debt figure; current liabilities total $1,488,744, consisting primarily of accounts payable and accrued expenses.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 97% ($436,000) for the quarter and 54% ($563,000) for the six months compared to the prior year periods. This was driven by a 174% increase in product revenues due to large-scale Protein A production orders.
• Revenue Composition: Research and development revenues dropped to zero for the current periods, down from $127,000 and $157,000 in the prior year, due to the absence of non-recurring licensing payments.
• Expense Trends: Total costs and expenses rose 16% for both the quarter and six-month periods. R&D expenses increased 14% year-to-date due to clinical program production costs. SG&A expenses remained relatively flat.
• Investment Income: Investment and interest income decreased 45% for the quarter and 39% year-to-date, attributed to lower interest rates and reduced average funds available for investment.
• Liquidity: Cash and cash equivalents decreased significantly from $16.2 million at March 31, 2001, to $3.6 million at September 30, 2001, primarily due to investing activities (purchasing marketable securities) and operating losses.

Guidance, Outlook, and Risks

• Clinical Pipeline: The company completed a Phase 2 trial for secretin in autism with statistically significant results and intends to initiate Phase 3 trials in 2002 pending FDA approval. Phase 2 trials for CTLA4-Ig (stem cell transplantation) were approved by the FDA in October 2000. A Phase 2 protocol for uridine (mitochondrial disease) is being prepared.
• Liquidity Outlook: Management believes current funding is sufficient to meet working capital and capital expenditure requirements for the next 24 months. However, there is no assurance that additional financing can be secured on favorable terms if needed.
• Legal Contingencies:
  • Pro-Neuron Litigation: Pro-Neuron, Inc. sued Repligen and UCSD to void a license agreement regarding uridine. Repligen intends to defend vigorously; a loss could limit commercialization of uridine.
  • BMS Patent Dispute: Repligen and the University of Michigan are litigating against Bristol-Myers Squibb regarding inventorship of CTLA4 patents. Failure to obtain shared ownership could restrict commercialization of CTLA4-Ig.
• Customer Concentration: One customer accounted for approximately 85% of revenues in the quarter ended September 30, 2001, and 80% of accounts receivable.

Investor Verification Checklist

• Verify the status of the FDA review for the synthetic porcine secretin product and the timeline for Phase 3 autism trials.
• Monitor the outcome of the Pro-Neuron, Inc. lawsuit regarding the UCSD uridine license.
• Assess the progress of the patent correction lawsuit against Bristol-Myers Squibb regarding CTLA4-Ig rights.
• Review the concentration risk associated with the single customer representing 85% of recent revenue.
• Confirm the sufficiency of the $27 million in cash and marketable securities to fund operations through the projected 24-month runway.